股本结构
单位：万股
| 公告日期 | 2024-03-27 | 2024-03-27 | 2023-11-07 | 2023-11-07 | 2023-08-10 | 2023-08-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 7089.53 | 7067.74 | 5372.89 | 5285.89 | 5268.64 | 5265.77 |
| 普通股本 | 7089.53 | 7067.74 | 5372.89 | 5285.89 | 5268.64 | 5265.77 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-22 | 2023-12-31 | 2023-11-03 | 2023-09-30 | 2023-08-04 | 2023-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-27 | 7089.53 | 未披露 | 定期报告 | 2024-03-22 |
| 2024-03-27 | 7067.74 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Exercise of stock options
Issuance of common stock upon cashless exercise of warrants
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
|
2023-12-31 |
| 2023-11-07 | 5372.89 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-07 | 5285.89 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
|
2023-09-30 |
| 2023-08-10 | 5268.64 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-10 | 5265.77 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock in at-the-market offerings, net
Vesting of restricted stock awards including withholding, net
|
2023-06-30 |
| 2023-05-11 | 4929.22 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-11 | 4928.67 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Exercise of stock options
|
2023-03-31 |
| 2023-02-28 | 4927.89 | 未披露 | 定期报告 | 2023-02-24 |
| 2023-02-28 | 4919.98 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Other increase
Issuance of common stock from Employee Stock Purchase Plan
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock related to contingent consideration liability
Exercise of stock options
Issuance of common stock upon cashless exercise of warrants
|
2022-12-31 |
| 2022-11-10 | 4915.91 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-10 | 4916.16 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
Other increase
|
2022-09-30 |
| 2022-08-16 | 4902.53 | 未披露 | 定期报告 | 2022-08-12 |
| 2022-08-11 | 4853.52 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-16 | 4814.63 | 未披露 | 定期报告 | 2022-08-01 |
| 2022-08-11 | 4637.21 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock related to contingent consideration liability
|
2022-06-30 |
| 2022-05-12 | 4321.94 | 未披露 | 定期报告 | 2022-05-10 |
| 2022-05-12 | 4321.99 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock upon exercise of warrants
Issuance of common stock from Employee Stock Purchase Plan
|
2022-03-31 |
| 2022-03-15 | 4322.27 | 未披露 | 定期报告 | 2022-03-11 |
| 2022-03-15 | 4099.38 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Retirement of common stock in exchange for common stock warrant
Issuance of common stock in at-the-market offerings, net
Issuance of common stock upon cashless exercise of warrants
|
2021-12-31 |
| 2021-11-09 | 3973.86 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-09 | 3970.28 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
|
2021-09-30 |
| 2021-08-16 | 3970.59 | 未披露 | 定期报告 | 2021-08-01 |
| 2021-08-10 | 3969.35 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at the market offerings, net
|
2021-06-30 |
| 2021-05-17 | 3839.68 | 未披露 | 定期报告 | 2021-05-14 |
| 2021-05-17 | 3825.72 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Retirement of common stock in exchange for common stock warrant
Issuance of common stock in at the market offering, net
Issuance of common stock upon cashless exercise of warrants
|
2021-03-31 |
| 2021-02-25 | 3715.04 | 未披露 | 定期报告 | 2021-02-23 |
| 2021-02-25 | 3714.29 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock from exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock and pre-funded warrants in public offering, net
Issuance of common stock in at-the-market offering, net
Issuance of common stock upon exercise of warrants
Issuance of common stock related to contingent consideration liability
|
2020-12-31 |
| 2020-11-09 | 3307.10 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-11-09 | 3307.30 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock from exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock and pre-funded warrants in public offering, net
Issuance of common stock in at the market offering, net
Issuance of common stock upon exercise of warrants
|
2020-09-30 |
| 2020-08-21 | 3291.18 | 未披露 | 定期报告 | 2020-08-10 |
| 2020-08-11 | 3290.43 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-08-21 | 3289.03 | 未披露 | 定期报告 | 2020-08-01 |
| 2020-07-16 | 3125.25 | 未披露 |
更多>>
1.Common stock offered by the company 3,369,564 shares.
2.The number of shares of common stock to be outstanding after the offering is based on 27,882,914 shares outstanding as of July 10, 2020.
|
2020-07-16 |
| 2020-07-13 | 2788.29 | 未披露 | 定期报告 | 2020-07-10 |
| 2020-08-11 | 2655.39 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at the market offering, net of offering costs
Issuance of common stock upon exercise of warrants
|
2020-06-30 |
| 2020-06-01 | 2011.17 | 未披露 | 定期报告 | 2020-05-29 |
| 2020-05-13 | 1552.69 | 未披露 | 定期报告 | 2020-05-13 |
| 2020-05-13 | 1535.95 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock upon exercise of warrants
|
2020-03-31 |
| 2020-03-27 | 1536.17 | 未披露 | 定期报告 | 2020-03-26 |
| 2020-03-27 | 1531.22 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Vesting and accelerated vesting of restricted stock, net
Issuance of common stock upon exercise of warrants
Issuance of common stock in registered direct offering, net of offering costs
Issuance of common stock for acquired in-process research and development
|
2019-12-31 |
| 2019-11-13 | 1533.81 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Stock based compensation and vesting of restricted stock
Issuance of common stock for acquired in-process research and development
|
2019-09-30 |
| 2019-08-13 | 1533.80 | 未披露 | 定期报告 | 2019-08-13 |
| 2019-08-22 | 1533.75 | 未披露 | 定期报告 | 2019-08-09 |
| 2019-08-13 | 1345.08 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Stock based compensation and vesting of restricted stock
|
2019-06-30 |
| 2019-05-14 | 1345.07 | 未披露 |
更多>>
From January 1, 2019 to March 31, 2019
Vesting and accelerated vesting of restricted stock
Issuance of common stock in registered direct offering, net of offering costs
Issuance of common stock upon exercise of warrants
|
2019-03-31 |
| 2019-04-01 | 1345.11 | 未披露 | 定期报告 | 2019-03-27 |
| 2019-04-01 | 907.82 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Stock based compensation
Vesting and accelerated vesting of restricted stock
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
Issuance of common stock and units in registered direct offerings, net of offering costs
Issuance of common units in public offering, net of offering costs
|
2018-12-31 |
| 2018-11-13 | 875.53 | 未披露 | 定期报告 | 2018-11-13 |
| 2018-11-13 | 172.56 | 未披露 |
更多>>
From January 1, 2018 to September 30, 2018
Vesting of restricted stock
Exercises of stock options
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
Issuance of common stock in registered direct offering, net of offering costs
|
2018-09-30 |
| 2018-09-26 | 143.39 | 未披露 | 定期报告 | 2018-09-24 |
| 2018-09-14 | 140.00 | 未披露 |
更多>>
On September 13, 2018, Altimmune, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a one-for-thirty (1:30) reverse split of the Company’s outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”). The Reverse Stock Split will reduce the number of the Company’s outstanding shares of common stock from approximately 43 million shares to approximately 1.4 million shares. The number of authorized shares of common stock will remain unadjusted as a result of the Reverse Stock Split. The Reverse Stock Split became effective after the close of market on September 13, 2018 and the consolidated common stock will begin trading on The Nasdaq Global Market on a split-adjusted basis on September 14, 2018.
|
2018-09-14 |
| 2018-08-17 | 3850.67 | 未披露 | 定期报告 | 2018-08-16 |
| 2018-08-14 | 3848.75 | 未披露 | 定期报告 | 2018-08-14 |
| 2018-07-26 | 3850.67 | 未披露 | 定期报告 | 2018-07-23 |
| 2018-08-14 | 3736.40 | 0.06 |
更多>>
From January 1, 2018 to June 30, 2018
Vesting of restricted stock
Exercises of stock options
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
|
2018-06-30 |
| 2018-07-26 | 3474.60 | 未披露 | 定期报告 | 2018-06-22 |
| 2018-04-30 | 2580.21 | 未披露 | 定期报告 | 2018-04-27 |
| 2018-05-15 | 2225.03 | 0.70 |
更多>>
From January 1, 2018 to March 31, 2018
Conversion of Series B redeemable convertible preferred stock into common stock
Exercises of stock options
Vesting of restricted stock
|
2018-03-31 |
| 2018-04-02 | 2227.11 | 未披露 | 定期报告 | 2018-03-30 |
| 2018-04-02 | 1810.37 | 1.22 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts
Conversion of Series B redeemable convertible preferred stock into common stock
Conversion of Series B convertible preferred stock into common stock
Vesting and accelerated vesting of restricted stock
Exercises of stock options
Conversion of convertible notes and accrued interest into common stock
Warrant exercises
Issuance of common stock for the acquisition of subsidiaries
|
2017-12-31 |
| 2017-11-09 | 1565.26 | 未披露 | 定期报告 | 2017-11-09 |
| 2017-11-09 | 1562.71 | 1.57 |
更多>>
From January 1, 2017 to September 30, 2017
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts
Conversion of Series B convertible preferred stock into common stock
Vesting and accelerated vesting of restricted stock
Exercises of stock options
Conversion of convertible notes and accrued interest into common stock
Warrant exercises
Issuance of common stock for the acquisition of subsidiaries
|
2017-09-30 |
| 2017-09-01 | 1558.61 | 未披露 | 定期报告 | 2017-08-18 |
| 2017-08-14 | 1542.29 | 未披露 | 定期报告 | 2017-08-08 |
| 2017-08-14 | 1542.49 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-05 | 1691.63 | 未披露 |
更多>>
Additionally, the company announced that immediately prior to the merger, it effectuated a 1-for-10 reverse stock split of outstanding shares of its common stock.
As of March 22, 2017, there were 9,195,906 shares of Altimmune Class A Common Stock, 38,836 shares of Altimmune Class B Common Stock and 800,000 shares of Altimmune Series B Convertible Preferred Stock for an aggregate of 10,034,742 shares of common stock (assuming conversion of all Class B Common Stock and Series B Convertible Preferred Stock into Class A Common Stock on a 1-for-1 basis, and re-designation of Altimmune’s Class A Common Stock as “common stock”).
|
2017-05-05 |
| 2015-11-06 | 6445.13 | 未披露 | 定期报告 | 2015-11-04 |
| 2015-11-06 | 6435.88 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-05 | 6422.44 | 未披露 | 定期报告 | 2015-08-03 |
| 2015-08-05 | 6391.22 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-07 | 6379.20 | 未披露 | 定期报告 | 2015-05-04 |
| 2015-04-30 | 6367.45 | 未披露 | 定期报告 | 2015-04-20 |
| 2015-05-07 | 6367.43 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-11 | 6363.29 | 未披露 | 定期报告 | 2015-03-03 |
| 2015-03-11 | 6360.33 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Shares issued upon exercise of warrants
Employee vesting of restricted shares
|
2014-12-31 |
| 2014-11-06 | 6337.36 | 未披露 | 定期报告 | 2014-11-03 |
| 2014-11-06 | 6221.60 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-05 | 5644.22 | 未披露 | 定期报告 | 2014-08-01 |
| 2014-08-04 | 5552.57 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-23 | 5454.20 | 未披露 | 定期报告 | 2014-05-15 |
| 2014-05-08 | 5447.61 | 未披露 | 定期报告 | 2014-05-01 |
| 2014-04-30 | 5427.62 | 未披露 | 定期报告 | 2014-04-17 |
| 2014-05-08 | 5377.37 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-11 | 5355.89 | 未披露 | 定期报告 | 2014-03-07 |
| 2014-03-11 | 5230.42 | 未披露 |
更多>>
from December 31,2012 to December 31,2013
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Employee vesting of restricted shares
|
2013-12-31 |
| 2013-11-07 | 5231.09 | 未披露 | 定期报告 | 2013-11-01 |
| 2013-11-07 | 5229.76 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-08 | 5231.09 | 未披露 | 定期报告 | 2013-08-02 |
| 2013-08-07 | 5117.39 | 未披露 | 定期报告 | 2013-06-30 |
| 2013-05-08 | 4946.07 | 未披露 | 定期报告 | 2013-05-02 |
| 2013-04-30 | 4884.51 | 未披露 | 定期报告 | 2013-04-18 |
| 2013-05-08 | 4841.65 | 未披露 | 定期报告 | 2013-03-31 |
| 2013-03-14 | 4836.60 | 未披露 | 定期报告 | 2013-02-28 |
| 2013-03-14 | 4835.27 | 未披露 |
更多>>
from DEC 31,2011 to DEC 31,2012
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
|
2012-12-31 |
| 2012-11-06 | 4836.60 | 未披露 | 定期报告 | 2012-11-01 |
| 2012-11-06 | 4834.60 | 未披露 | 定期报告 | 2012-09-30 |
| 2012-08-07 | 4836.60 | 未披露 | 定期报告 | 2012-08-01 |
| 2012-08-07 | 4834.60 | 未披露 | 定期报告 | 2012-06-30 |
| 2012-05-10 | 4833.45 | 未披露 | 定期报告 | 2012-05-01 |
| 2012-05-08 | 4831.45 | 未披露 | 定期报告 | 2012-03-31 |
| 2012-03-08 | 4835.70 | 未披露 | 定期报告 | 2012-02-29 |
| 2012-03-08 | 4823.62 | 未披露 |
更多>>
from December 31, 2010 to December 31, 2011
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
|
2011-12-31 |
| 2011-11-09 | 4828.21 | 未披露 | 定期报告 | 2011-10-31 |
| 2011-11-09 | 4819.40 | 未披露 | 定期报告 | 2011-09-30 |
| 2011-08-11 | 4823.21 | 未披露 | 定期报告 | 2011-08-04 |
| 2011-08-11 | 4819.40 | 未披露 | 定期报告 | 2011-06-30 |
| 2011-05-11 | 4636.01 | 未披露 | 定期报告 | 2011-05-04 |
| 2011-05-11 | 4632.20 | 未披露 | 定期报告 | 2011-03-31 |
| 2011-03-31 | 4637.06 | 未披露 | 定期报告 | 2011-03-24 |
| 2011-03-31 | 4623.82 | 未披露 |
更多>>
from DEC 31,2009 to DEC 31,2010
Issuance of common stock, net issuance costs
Exercise of stock purchase warrants
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
Conversion of July 2009 Convertible Debt
|
2010-12-31 |
| 2010-11-15 | 4090.87 | 未披露 | 定期报告 | 2010-11-09 |
| 2010-11-15 | 3264.33 | 未披露 | 定期报告 | 2010-09-30 |
| 2010-08-13 | 3276.99 | 未披露 | 定期报告 | 2010-08-09 |
| 2010-08-13 | 2985.73 | 未披露 | 定期报告 | 2010-06-30 |
From December 31, 2022 to December 31, 2023
Exercise of stock options
Issuance of common stock upon cashless exercise of warrants
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
From June 30, 2023 to September 30, 2023
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
From March 31, 2023 to June 30, 2023
Issuance of common stock in at-the-market offerings, net
Vesting of restricted stock awards including withholding, net
From December 31, 2022 to March 31, 2023
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Exercise of stock options
From December 31, 2021 to December 31, 2022
Other increase
Issuance of common stock from Employee Stock Purchase Plan
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock related to contingent consideration liability
Exercise of stock options
Issuance of common stock upon cashless exercise of warrants
From June 30, 2022 to September 30, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock from Employee Stock Purchase Plan
Other increase
From March 31, 2022 to June 30, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock related to contingent consideration liability
From December 31, 2021 to March 31, 2022
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at-the-market offerings, net
Issuance of common stock upon exercise of warrants
Issuance of common stock from Employee Stock Purchase Plan
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Retirement of common stock in exchange for common stock warrant
Issuance of common stock in at-the-market offerings, net
Issuance of common stock upon cashless exercise of warrants
From June 30, 2021 to September 30, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
From March 31, 2021 to June 30, 2021
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at the market offerings, net
From December 31, 2020 to March 31, 2021
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Retirement of common stock in exchange for common stock warrant
Issuance of common stock in at the market offering, net
Issuance of common stock upon cashless exercise of warrants
From December 31, 2019 to December 31, 2020
Issuance of common stock from exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock and pre-funded warrants in public offering, net
Issuance of common stock in at-the-market offering, net
Issuance of common stock upon exercise of warrants
Issuance of common stock related to contingent consideration liability
From June 30, 2020 to September 30, 2020
Issuance of common stock from exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock and pre-funded warrants in public offering, net
Issuance of common stock in at the market offering, net
Issuance of common stock upon exercise of warrants
1.Common stock offered by the company 3,369,564 shares.
2.The number of shares of common stock to be outstanding after the offering is based on 27,882,914 shares outstanding as of July 10, 2020.
From March 31, 2020 to June 30, 2020
Exercise of stock options
Vesting of restricted stock awards including withholding, net
Issuance of common stock in at the market offering, net of offering costs
Issuance of common stock upon exercise of warrants
From January 1, 2020 to March 31, 2020
Vesting of restricted stock awards including withholding, net
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock upon exercise of warrants
From December 31, 2018 to December 31, 2019
Vesting and accelerated vesting of restricted stock, net
Issuance of common stock upon exercise of warrants
Issuance of common stock in registered direct offering, net of offering costs
Issuance of common stock for acquired in-process research and development
From June 30, 2019 to September 30, 2019
Stock based compensation and vesting of restricted stock
Issuance of common stock for acquired in-process research and development
From March 31, 2019 to June 30, 2019
Stock based compensation and vesting of restricted stock
From January 1, 2019 to March 31, 2019
Vesting and accelerated vesting of restricted stock
Issuance of common stock in registered direct offering, net of offering costs
Issuance of common stock upon exercise of warrants
From December 31, 2017 to December 31, 2018
Stock based compensation
Vesting and accelerated vesting of restricted stock
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
Issuance of common stock and units in registered direct offerings, net of offering costs
Issuance of common units in public offering, net of offering costs
From January 1, 2018 to September 30, 2018
Vesting of restricted stock
Exercises of stock options
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
Issuance of common stock in registered direct offering, net of offering costs
On September 13, 2018, Altimmune, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a one-for-thirty (1:30) reverse split of the Company’s outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”). The Reverse Stock Split will reduce the number of the Company’s outstanding shares of common stock from approximately 43 million shares to approximately 1.4 million shares. The number of authorized shares of common stock will remain unadjusted as a result of the Reverse Stock Split. The Reverse Stock Split became effective after the close of market on September 13, 2018 and the consolidated common stock will begin trading on The Nasdaq Global Market on a split-adjusted basis on September 14, 2018.
From January 1, 2018 to June 30, 2018
Vesting of restricted stock
Exercises of stock options
Conversion of Series B redeemable convertible preferred stock into common stock
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative
Issuance of common stock for the exchange of warrants
From January 1, 2018 to March 31, 2018
Conversion of Series B redeemable convertible preferred stock into common stock
Exercises of stock options
Vesting of restricted stock
from December 31, 2016 to December 31, 2017
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts
Conversion of Series B redeemable convertible preferred stock into common stock
Conversion of Series B convertible preferred stock into common stock
Vesting and accelerated vesting of restricted stock
Exercises of stock options
Conversion of convertible notes and accrued interest into common stock
Warrant exercises
Issuance of common stock for the acquisition of subsidiaries
From January 1, 2017 to September 30, 2017
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts
Conversion of Series B convertible preferred stock into common stock
Vesting and accelerated vesting of restricted stock
Exercises of stock options
Conversion of convertible notes and accrued interest into common stock
Warrant exercises
Issuance of common stock for the acquisition of subsidiaries
Additionally, the company announced that immediately prior to the merger, it effectuated a 1-for-10 reverse stock split of outstanding shares of its common stock.
As of March 22, 2017, there were 9,195,906 shares of Altimmune Class A Common Stock, 38,836 shares of Altimmune Class B Common Stock and 800,000 shares of Altimmune Series B Convertible Preferred Stock for an aggregate of 10,034,742 shares of common stock (assuming conversion of all Class B Common Stock and Series B Convertible Preferred Stock into Class A Common Stock on a 1-for-1 basis, and re-designation of Altimmune’s Class A Common Stock as “common stock”).
from December 31, 2013 to December 31, 2014
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Shares issued upon exercise of warrants
Employee vesting of restricted shares
from December 31,2012 to December 31,2013
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Employee vesting of restricted shares
from DEC 31,2011 to DEC 31,2012
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
from December 31, 2010 to December 31, 2011
Issuance of common stock, net issuance costs
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
from DEC 31,2009 to DEC 31,2010
Issuance of common stock, net issuance costs
Exercise of stock purchase warrants
Shares issued upon exercise of stock options
Employee vesting of restricted shares, net
Conversion of July 2009 Convertible Debt